A phase III clinical study has delivered encouraging results for Moderna’s experimental mRNA-based cancer vaccine. Researchers reported that the treatment significantly reduced the risk of melanoma returning in high-risk patients. The vaccine trains the immune system to identify and attack cancer cells more effectively, building on the same mRNA technology that transformed vaccine development during the pandemic. Experts believe the results may accelerate the adoption of personalized cancer immunotherapy worldwide.
About the Author
